This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Merck (MRK) Tops on Q1 Earnings & Sales, Stock Up
by Zacks Equity Research
Merck (MRK) beats estimates for earnings as well as sales in first-quarter 2019. Stock is up in pre-market trading.
AstraZeneca's (AZN) Q1 Earnings Beat, New Drugs Drive Sales
by Zacks Equity Research
AstraZeneca (AZN) beats earnings and sales estimates in the first quarter. New drugs, especially cancer drugs, drive revenues.
Alkermes (ALKS) Reports Narrower-Than-Expected Loss in Q1
by Zacks Equity Research
Alkermes (ALKS) reports narrower-than-expected loss and sales beat in the first quarter of 2019.
Bristol-Myers Q1 Earnings Beat, Sales Up on Strong Eliquis
by Zacks Equity Research
Bristol-Myers (BMY) Q1 earnings and sales beat estimates on strong performance of Eliquis and Opdivo.
Can Keytruda Drive Merck's (MRK) Q1 Earnings and Sales?
by Zacks Equity Research
Merck's (MRK) relatively newer products like Keytruda, Gardasil and Bridion are likely to drive first-quarter sales. However, genericization of key drugs and increasing competition are concerns.
Merck (MRK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Merck (MRK) closed at $74.73 in the latest trading session, marking a +0.17% move from the prior day.
What's in the Cards for AstraZeneca (AZN) in Q1 Earnings?
by Zacks Equity Research
AstraZeneca (AZN) will report first-quarter results on Apr 26. New drugs likely to drive sales.
The Zacks Analyst Blog Highlights: Wells Fargo, UnitedHealth, Merck, Schwab and Raytheon
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Wells Fargo, UnitedHealth, Merck, Schwab and Raytheon
Earnings Preview: Merck (MRK) Q1 Earnings Expected to Decline
by Zacks Equity Research
Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Clovis Focuses on Rubraca Label Expansion, Competition Stiff
by Zacks Equity Research
Although sales of Clovis' (CLVS) Rubraca improved in the fourth quarter of 2018, the drug may face significant competition going forward. Clovis is also evaluating Rubrca for other cancer indications.
Can Q1 Earnings Lift Healthcare ETFs Higher?
by Sweta Killa
With negative earnings revisions, the healthcare sector is expected to witness earnings growth of 1.8% in the first quarter, suggesting smooth trading for healthcare ETFs.
Here Are the Key Takeaways From J&J's Q1 Earnings Report
by Zacks Equity Research
Let's have a look at some of the highlights of J&J's (JNJ) first-quarter 2019 results.
Novo Nordisk's (NVO) Share Price Rises YTD on Strong Pipeline
by Zacks Equity Research
Share price of Novo Nordisk (NVO) has increased year to date on strong presence in the Diabetes Care market and a solid pipeline.
Gilead Collaborates With Insitro to Develop NASH Therapies
by Zacks Equity Research
Gilead (GILD) collaborates with data-driven company, Insitro, to harness the power of computers to discover and develop therapies for treating NASH (fatty liver).
Top Analyst Reports for Wells Fargo, UnitedHealth & Merck
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Wells Fargo (WFC), UnitedHealth (UNH) and Merck (MRK).
J&J (JNJ) Beats on Q1 Earnings, Ups 2019 Sales Growth View
by Zacks Equity Research
J&J (JNJ) beats estimates for both earnings and sales in the first quarter of 2019 and raises 2019 guidance for operational sales and adjusted operational EPS growth. Shares up in pre-market trading.
Why Merck (MRK) is a Top Dividend Stock for Your Portfolio
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
Merck (MRK) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $78.53, moving -1.13% from the previous trading session.
Bristol-Myers' Shareholders Vote for Celgene Acquisition
by Zacks Equity Research
Bristol-Myers' (BMY) gets a green signal from a majority of its shareholders for the merger with Celgene Corporation.
J&J's Erdafitinib Gets FDA Approval for Urothelial Cancer
by Zacks Equity Research
FDA grants approval to J&J's (JNJ) erdafitinib for metastatic urothelial cancer, a type of bladder cancer. This is J&J's second FDA approval for a new drug in less than two months
Merck's Keytruda Gets FDA Nod for Expanded Lung Cancer Group
by Zacks Equity Research
Merck (MRK) gets FDA approval to include overall survival data from the KEYNOTE-042 study on Keytruda's label.
Pharma Stock Roundup: AZN, MRK, GSK Get Regulatory Approvals, Sandoz Inks New Deal
by Kinjel Shah
Glaxo (GSK) gets FDA approval for a new HIV medicine, Dovato. AstraZeneca (AZN)/Merck's (MRK) Lynparza gets approval in EU for metastatic breast cancer.
Intercept Reports Additional Positive Data From NASH Study
by Zacks Equity Research
Intercept Pharmaceuticals (ICPT) reports positive additional supportive data from its phase III REGENERATE study of obeticholic acid in patients with liver fibrosis due to NASH.
Seattle Genetics' Adcetris Progresses Well Amid Competition
by Zacks Equity Research
Seattle Genetics (SEGN) focuses on improving sales of its flagship product, Adcetris. The drug's label expansion programs also appear encouraging.
Amgen's (AMGN) Osteoporosis Drug Evenity Gets FDA Approval
by Zacks Equity Research
Amgen (AMGN) gets approval in the United States for osteoporosis drug, Evenity.